SynthesisBMC endocrine disorders2026
B vitamins and metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review of observational studies.
Synthesis in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundB vitamins are crucial cofactors in metabolic regulation; however, their role in the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. Evidence for individual B vitamins is often contradictory. This systematic review evaluated the findings of observational studies examining the association between B vitamin intake and MASLD risk, severity, and outcomes.
methodsA systematic search was conducted in PubMed, Scopus, Web of Science, and Google Scholar for studies published up to January 2026, adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. All included studies were observational in design, encompassing cross-sectional, case-control, cohort, and Mendelian randomization (MR) studies that assessed dietary, supplemental, or biological B-vitamin status in relation to MASLD diagnoses. Study quality was evaluated using the Newcastle-Ottawa scale (NOS). No quantitative meta-analysis was performed and the evidence was narratively synthesized.
resultsFifty-nine studies were included (38 cross-sectional, 13 case-control, 6 cohort, and 2 MR studies). Folate has been extensively studied, with most evidence suggesting a protective role for serum folate and 5-mTHF against MASLD and fibrosis. However, this was contradicted by positive associations for RBC folate and unmetabolized folic acid (UMFA). Cohort studies have linked higher folate status to reduced all-cause mortality. Vitamin B12 findings were highly controversial, with studies reporting protective, detrimental, and null associations; MR studies suggested a positive causal link with MASLD risk. Choline intake was inversely associated with steatosis but positively correlated with fibrosis in specific subgroups, including men and postmenopausal women. Evidence for niacin and pyridoxine was inconsistent, though often suggesting an inverse relationship with MASLD.
conclusionObservational evidence suggests significant, albeit contradictory, associations between specific B-vitamins (particularly folate and B12), choline, and MASLD progression. However, given the massive methodological heterogeneity and heavy reliance on cross-sectional data, the certainty of these findings is very low. The inherent uncertainty of these associations rather than concluding a probable clinical benefit should also be emphasized. Rigorous prospective cohorts and randomized controlled trials are required to establish causality and clarify the true clinical utility of B-vitamin status in MASLD.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.